Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
<p>Use of adjuvant hormone therapy across 10 years in women diagnosed with breast cancer in Stockholm, Sweden, 2005–2020. The dashed vertical lines indicate six months after finishing 5 years of adjuvant hormone therapy—a period that was used to define therapy extension.</p>
Сохранить в:
| Главный автор: | |
|---|---|
| Другие авторы: | , , , |
| Опубликовано: |
2025
|
| Предметы: | |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
| _version_ | 1849927639748313088 |
|---|---|
| author | Erwei Zeng (14958443) |
| author2 | Wei He (14958446) Arvid Sjölander (14958449) Jenny Bergqvist (14958452) Kamila Czene (14958455) |
| author2_role | author author author author |
| author_facet | Erwei Zeng (14958443) Wei He (14958446) Arvid Sjölander (14958449) Jenny Bergqvist (14958452) Kamila Czene (14958455) |
| author_role | author |
| dc.creator.none.fl_str_mv | Erwei Zeng (14958443) Wei He (14958446) Arvid Sjölander (14958449) Jenny Bergqvist (14958452) Kamila Czene (14958455) |
| dc.date.none.fl_str_mv | 2025-11-24T22:42:31Z |
| dc.identifier.none.fl_str_mv | 10.1158/0008-5472.30699299 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_2_from_Determinants_and_Effectiveness_of_Extending_the_Duration_of_Adjuvant_Hormone_Therapy_beyond_5_Years_in_Patients_with_Breast_Cancer/30699299 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Cancer Care and Survivorship Epidemiology Breast Cancer Epidemiology Survivorship Research Epidemiology of survivorship |
| dc.title.none.fl_str_mv | Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Use of adjuvant hormone therapy across 10 years in women diagnosed with breast cancer in Stockholm, Sweden, 2005–2020. The dashed vertical lines indicate six months after finishing 5 years of adjuvant hormone therapy—a period that was used to define therapy extension.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_5c1bcdecb3dbc43e78443aae13007a52 |
| identifier_str_mv | 10.1158/0008-5472.30699299 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30699299 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast CancerErwei Zeng (14958443)Wei He (14958446)Arvid Sjölander (14958449)Jenny Bergqvist (14958452)Kamila Czene (14958455)CancerCancer Care and SurvivorshipEpidemiologyBreast CancerEpidemiologySurvivorship ResearchEpidemiology of survivorship<p>Use of adjuvant hormone therapy across 10 years in women diagnosed with breast cancer in Stockholm, Sweden, 2005–2020. The dashed vertical lines indicate six months after finishing 5 years of adjuvant hormone therapy—a period that was used to define therapy extension.</p>2025-11-24T22:42:31ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/0008-5472.30699299https://figshare.com/articles/figure/Figure_2_from_Determinants_and_Effectiveness_of_Extending_the_Duration_of_Adjuvant_Hormone_Therapy_beyond_5_Years_in_Patients_with_Breast_Cancer/30699299CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/306992992025-11-24T22:42:31Z |
| spellingShingle | Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer Erwei Zeng (14958443) Cancer Cancer Care and Survivorship Epidemiology Breast Cancer Epidemiology Survivorship Research Epidemiology of survivorship |
| status_str | publishedVersion |
| title | Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| title_full | Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| title_fullStr | Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| title_full_unstemmed | Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| title_short | Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| title_sort | Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| topic | Cancer Cancer Care and Survivorship Epidemiology Breast Cancer Epidemiology Survivorship Research Epidemiology of survivorship |